CFO
SANA icon

Callan Family Office’s Sana Biotechnology SANA Stock Holding History

Callan Family Office’s Portfolio SANA Stock Details SANA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$35.2K Sell
12,224
-3,808
-24% -$15K ﹤0.01% 1117
2025
Q4 		$65.3K Buy
+16,032
New +$71.8K ﹤0.01% 1086

Other funds holding SANA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MG
Marex Group London $15.8B AUM 31.44% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return

Callan Family Office's SANA Position: Q1 2026 in Review

Callan Family Office reduced its Sana Biotechnology (SANA) stake by 24% in Q1 2026, selling an estimated $15K and leaving 12,224 shares worth $35.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1117.

Callan Family Office first reported a position in SANA in Q4 2025 and has held it in 2 quarters since. The position peaked at $65.3K in Q4 2025. 202 funds tracked by Wall St. Rank hold SANA as of Q1 2026.

  • Callan Family Office held 12,224 shares of Sana Biotechnology worth $35.2K as of Q1 2026.
  • Callan Family Office sold 3,808 Sana Biotechnology shares in Q1 2026, an estimated $15K.
  • Sana Biotechnology made up ﹤0.01% of Callan Family Office's portfolio in Q1 2026, its #1117 holding.
  • Callan Family Office first reported a position in Sana Biotechnology in Q4 2025 and has held it in 2 quarters since.
  • Callan Family Office's Sana Biotechnology position peaked at $65.3K in Q4 2025.
  • 202 funds tracked by Wall St. Rank held Sana Biotechnology as of Q1 2026.

Based on Callan Family Office's 13F filing for Q1 2026, filed 13 May 2026.